何胜悦,何常
HE Shengyue,HE Chang

• 1:贵州医科大学病理科
• 2:贵州医科大学附院病理科

摘要(Abstract)：

目的:探讨程序性死亡因子4(PDCD4)、5(PDCD5)及髓样细胞白血病-1(MCL-1)在结直肠癌(CRC)中表达及意义。方法:应用免疫组化检测PDCD4、PDCD5与MCL-1在CRC(50例)、结直肠腺瘤(20例)和结直肠黏膜慢性炎症(20例)中的表达,同时分析PDCD4、PDCD5及MCL-1蛋白的表达与CRC患者淋巴结转移、生存期及TNM分期的关系,采用spearman's方法分析结直肠组织中MCL-1、PDCD4及PDCD5蛋白表达的相关性。结果:PDCD4、PDCD5及MCL-1在CRC、结直肠腺瘤、结直肠黏膜慢性炎症中的阳性表达率分别比较,差异有统计学意义(P<0.05);CRC患者标本中,MCL-1与PDCD4(r=-0.401,P<0.05)、PDCD5(r=-0.445,P<0.05)表达呈负相关,而PDCD4与PDCD5的表达呈正相关(r=0.510,P<0.05);PDCD4及MCL-1在CRC组织中的表达与TNM分期、淋巴结转移及5年生存期有关(P<0.05)。结论:CRC发生及发展与PDCD4、PDCD5及MCL-1的蛋白表达有关。
Objective: To explore the expression and clinical significance of PDCD4,PDCD5 and MCL-1 in colorectal cancer( CRC). Methods: The immunohistochemistry was adopted to detect protein levels of PDCD4,PDCD5 and MCL-1 in 50 cases of colorectal cancer,20 cases of colorectal adenoma and 20 cases of colorectal inflammation. At the same time,the correlation between the expression of PDCD4,PDCD5 and MCL-1 and lymph node metastasis,survival length and TNM staging in patients with colorectal carcinoma was analyzed,and Spearman 's method was adopted to analyze the correlation between expression of PDCD4,PDCD5 and MCL-1. Results: There were statistically significant differences in PDCD4,PDCD5 and MCL-1 positive expression rate in the CRC,colorectal adenoma and colorectal inflammation( P < 0. 05). In CRC patient specimens,MCL-1expresion was negatively correlated with PDCD4 expression( r =- 0. 401,P < 0. 05) and PDCD5( r =- 0. 445,P <0. 05) while PDCD4 expression was positively correlated with PDCD5 expression( r = 0. 510,P <0. 05). PDCD4 and MCL-1 expressions in CRC tissues were associated with TNM staging,lymph node metastasis and 5 years survival( P < 0. 05). Conclusion: The occurrence and development of CRC is correlated with the expression of PDCD4,PDCD5 and MCL-1.

关键词(KeyWords)： 结直肠肿瘤;程序性细胞死亡因子;髓样细胞白血病-1;免疫组织化学
colorectal cancer;programmed cell death factor;myeloid cell leukemia-1;immunohis tochemistry

Abstract:

Keywords:

基金项目(Foundation): 贵州省科技厅基金(E2010-4)

作者(Author): 何胜悦,何常
HE Shengyue,HE Chang

DOI: 10.19367/j.cnki.1000-2707.2016.08.015

参考文献(References)：

• [1]宋晓昕.Fascin、β-catenin、E-cadherin在大肠管状腺瘤癌变过程中的表达及意义[J].河北医药,2010(16):2178-2180.
• [2]Itani S,Kunisada T,Morimoto Y,et al.MicroRNA-21correlates with tumorigenesis in malignant peripheral nerve sheath tumor(MPNST)via programmed cell death protein 4(PDCD4)[J].J Cancer Res Clin Oncol,2012(9):1501-1509.
• [3]Wedeken L,Singh P,Klempnauer KH.Tumor suppressor protein Pdcd4 inhibits translation of p53 mRNA[J].J Biol Chem,2011(50):42855-42862.
• [4]Wang L,Wang C,Su B,et al.Recombinant human PDCD5protein enhances chemosensitivity of breast cancer in vitro and in vivo[J].Biochem Cell Biol,2013(6):526-531.
• [5]Tsutsui M,Yasuda H,Suto H,et al.Frequent STAT3activation is associated with Mcl-1 expression in nasal NK-cell lymphoma[J].Int J Lab Hematol,2010(4):419-426.
• [6]Fassan M,Pizzi M,Battaqlia G,et al.Programmed cell death 4(PDCD4)expression during muhistep Barrett’s carcinogenesis[J].J Clin Pathol,2011(3):274.
• [7]Wang W,Zhao J,Wang H,et al.Progammed cell death4(PDCD4)mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down mgulmi on of FLIP expression[J].Exp Cel l Res,2010(15):2456-2464.
• [8]Xu L,Hu J,Zhao Y,et al.PDCD5 interacts with p53and functions as a positive regulator in the p53 pathway[J].Apoptosis,2012(11):1235-1245.
• [9]Chen C,Zhou H,Xu L,et al.Recombinant human PDCD5sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo[J].Apoptosis,2010(7):805-813.
• [10]Shi L,Song Q,Zhang Y,et al.Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells[J].Biochem Biophys Res Commun,2010(2):224-230.
• [11]王孟昌,张斌.髓样细胞白血病-1基因在多发性骨髓瘤发病中的分子机制[J].西安交通大学学报:医学版,2011(4):429-432.

文章评论(Comment)：